NEW YORK, NY / ACCESSWIRE / March 10, 2022 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court. Further details about the cases can be found at the links provided. There is no cost or obligation to you.
SLI Shareholders Click Here: https://www.zlk.com/pslra-1/standard-lithium-ltd-loss-submission-form?prid=24548&wire=1
EDU Shareholders Click Here: https://www.zlk.com/pslra-1/new-oriental-education-technology-group-inc-loss-submission-form?prid=24548&wire=1
FENC Shareholders Click Here: https://www.zlk.com/pslra-1/fennec-pharmaceuticals-inc-loss-submission-form?prid=24548&wire=1
* ADDITIONAL INFORMATION BELOW *
Standard Lithium Ltd. (NYSE:SLI)
SLI Lawsuit on behalf of: investors who purchased May 19, 2020 – November 17, 2021
Lead Plaintiff Deadline : March 28, 2022
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/standard-lithium-ltd-loss-submission-form?prid=24548&wire=1
According to the filed complaint, during the class period, Standard Lithium Ltd. made materially false and/or misleading statements and/or failed to disclose that: (i) the LiSTR Direct Lithium Extraction technology’s extraction recovery efficiencies were overstated; (ii) accordingly, the Company’s final product lithium recovery percentage at the Demonstration Plant would not be as high as the Company had represented to investors; and (iii) as a result, the Company’s public statements were materially false and misleading at all relevant times.
New Oriental Education & Technology Group Inc. (NYSE:EDU)
EDU Lawsuit on behalf of: investors who purchased April 24, 2018 – July 22, 2021
Lead Plaintiff Deadline : April 5, 2022
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/new-oriental-education-technology-group-inc-loss-submission-form?prid=24548&wire=1
According to the filed complaint, during the class period, New Oriental Education & Technology Group Inc. made materially false and/or misleading statements and/or failed to disclose that: (a) New Oriental’s revenue and operational growth was the result of deceptive marketing tactics and abusive business practices that flouted Chinese regulations and policies and exposed the Company to an extreme risk that more draconian measures would be imposed on the Company; (b) New Oriental had engaged in misleading and fraudulent advertising practices, including the provision of false and misleading discount Information designed to obfuscate the true cost of the Company’s programs to its customers; (c) New Oriental had falsified teacher qualifications and experience in order to attract customers and increase student enrollments; (d) New Oriental had defied prior government warnings against linking school enrollments with the provision of private tutoring services; (e) as a result of the foregoing, New Oriental was subject to an extreme undisclosed risk of adverse enforcement actions, regulatory fines and penalties, and the imposition of new rules and regulations adverse to the Company’s business and interests; and (f) as a result of the foregoing, defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and lacked a reasonable, factual basis.
Fennec Pharmaceuticals Inc. (NASDAQ:FENC)
FENC Lawsuit on behalf of: investors who purchased May 28, 2021 – November 26, 2021
Lead Plaintiff Deadline : April 11, 2022
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/fennec-pharmaceuticals-inc-loss-submission-form?prid=24548&wire=1
According to the filed complaint, during the class period, Fennec Pharmaceuticals Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) Fennec had not successfully remediated, and overstated its efforts to remediate, issues with the manufacturing facility of its drug product manufacturer for PEDMARK, a new compound developed to reduce the incidence of hearing loss in children undergoing chemotherapy; (ii) as a result, the Food and Drug Administration likely to approve the Resubmitted Pedmark New Drug Application (“NDA”); (iii) accordingly, the regulatory and commercial prospects of the Resubmitted Pedmark NDA were overstated; and (iv) as a result, the Company’s public statements were materially false and misleading at all relevant times.
You have until the lead plaintiff deadlines to request that the court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky is a nationally recognized firm with offices in New York, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Eduard Korsinsky, Esq.
55 Broadway, 10th Floor
New York, NY 10006
[email protected]
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com
SOURCE : Levi & Korsinsky, LLP
View source version on accesswire.com:
https://www.accesswire.com/692570/CLASS-ACTION-UPDATE-for-SLI-EDU-and-FENC-Levi-Korsinsky-LLP-Reminds-Investors-of-Class-Actions-on-Behalf-of-Shareholders